CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 631588-631788
Annnotations
CORD-19-Sentences
{"project":"CORD-19-Sentences","denotations":[{"id":"T60870","span":{"begin":0,"end":200},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The primary objective was to evaluate the safety and tolerability of repeated escalating doses of CIC (50-800 mcg/day) given as a nasal spray for 14 days to healthy and asymptomatic subjects with SAR."}
CORD-19_Custom_license_subset
{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T16","span":{"begin":0,"end":200},"obj":"Sentence"}],"text":"The primary objective was to evaluate the safety and tolerability of repeated escalating doses of CIC (50-800 mcg/day) given as a nasal spray for 14 days to healthy and asymptomatic subjects with SAR."}
CORD-19-PD-MONDO
{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T5886","span":{"begin":22,"end":25},"obj":"Disease"}],"attributes":[{"id":"A5886","pred":"mondo_id","subj":"T5886","obj":"http://purl.obolibrary.org/obo/MONDO_0010518"}],"text":"The primary objective was to evaluate the safety and tolerability of repeated escalating doses of CIC (50-800 mcg/day) given as a nasal spray for 14 days to healthy and asymptomatic subjects with SAR."}